Non-Compliance by Indian Drug Manufacturer: Cross Contamination
Recommendation

Thursday, 12 February 2026 9 .00 - 17.00 h
Best Practice for Manual and Automated Visual Inspection of Parenterals
So-called Non-Compliance reports are summaries of inspections conducted by European inspectors. They are publicly available on the EMA’s (European Medicines Agency) website. In the present case, the Non-Compliance Report is based on the inspection of an Indian pharmaceutical manufacturer in Bangalore, which was conducted by the MHRA in November 2017.
The report concerns the manufacturing of non-sterile dosage forms: tablets and capsules as well as their primary and secondary packaging. The inspectors found the cleaning procedure and the proof of cleaning success during product changes to be inadequate. As a result of the inspection, the GMP certificate was withdrawn. Due to the severity of the deficiencies found and the resulting cross contamination risk, the MHRA recommends a precautionary recall of all affected batches in the market.
Source: EudraGMDP Database
Related GMP News
04.02.2026Endotoxins Testing: Potential Change for WFI and Steam in the USP
04.02.2026Microbiological Deviations and Technical Deficiencies - Warning Letter to US Manufacturer
28.01.2026Changes to the 'Water Monographs' in the European Pharmacopoeia
21.01.2026Deficient Water System: Warning Letter to US Manufacturer
17.12.2025FDA publishes new Draft Guideline on GMP for Medical Gases
10.12.2025VDI 6022 Sheet 8.1 published: Qualification for the cleaning of air-conditioning systems


